Marksans Pharma Past Earnings Performance
Past criteria checks 2/6
Marksans Pharma has been growing earnings at an average annual rate of 13.5%, while the Pharmaceuticals industry saw earnings growing at 15% annually. Revenues have been growing at an average rate of 16.2% per year. Marksans Pharma's return on equity is 13.8%, and it has net margins of 14.2%.
Key information
13.45%
Earnings growth rate
10.68%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.49% |
| Revenue growth rate | 16.24% |
| Return on equity | 13.76% |
| Net Margin | 14.16% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Analysis Article • May 29
Earnings Beat: Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Marksans Pharma Limited ( NSE:MARKSANS ) defied analyst predictions to release its full-year results, which were ahead...Analysis Article • May 28
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • Feb 10
Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...Analysis Article • Jan 15
Marksans Pharma Limited's (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 22.2x...Analysis Article • Dec 09
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Nov 17
Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...
Narrative Update • Nov 11
MARKSANS: Upcoming Board Meeting And UK Regulatory Success Will Drive Momentum
Analysts have reduced their price target for Marksans Pharma from ₹231.67 to ₹216.67. They cite slight increases in the discount rate and a modest drop in the company's projected future price-to-earnings ratio as reasons for the adjustment.Analysis Article • Oct 15
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Narrative Update • Aug 15
Developed Markets Will Support Affordable Generic Expansion
Marksans Pharma's consensus price target has been revised downward, primarily due to sharply reduced revenue growth forecasts and a decline in net profit margin, lowering the fair value estimate from ₹301.00 to ₹231.67. What's in the News Board re-appointed Mr. Mark Saldanha as Managing Director, subject to shareholder approval at the upcoming AGM.Analysis Article • Aug 15
Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Analysis Article • Aug 07
Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Analysis Article • Jun 28
Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Marksans Pharma fair value estimate is ₹239 With ₹253 share...Analysis Article • May 27
We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings
Marksans Pharma Limited's ( NSE:MARKSANS ) robust recent earnings didn't do much to move the stock. However the...Analysis Article • May 22
₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Analysis Article • May 14
Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • Mar 23
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Mar 05
Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 24.6x...Analysis Article • Feb 15
Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a mediocre week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with the stock dropping 15% to...Analysis Article • Feb 01
Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Marksans Pharma's estimated fair value is ₹190 based on 2 Stage Free Cash Flow to Equity Marksans Pharma's...
New Narrative • Jan 28
Teva Pharma Facility And US Expansion To Strengthen Future Outlook
Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.Analysis Article • Nov 27
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Marksans Pharma Limited ( NSE:MARKSANS ) shares have been powering on, with a gain of...Analysis Article • Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Marksans Pharma Limited ( NSE:MARKSANS ) shares have continued their recent momentum with a 45% gain in the last month...Analysis Article • Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Marksans Pharma Limited ( NSE:MARKSANS ) shareholders would be excited to see that the share price has had a great...Analysis Article • Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
The market shrugged off Marksans Pharma Limited's ( NSE:MARKSANS ) solid earnings report. We did some digging and...Analysis Article • May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider...Analysis Article • Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Marksans Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 29,509 | 4,179 | 4,209 | 0 |
| 31 Dec 25 | 28,033 | 3,603 | 4,231 | 0 |
| 30 Sep 25 | 27,307 | 3,517 | 3,996 | 0 |
| 30 Jun 25 | 26,522 | 3,501 | 3,799 | 0 |
| 31 Mar 25 | 26,228 | 3,806 | 3,620 | 0 |
| 31 Dec 24 | 24,744 | 3,683 | 3,451 | 0 |
| 30 Sep 24 | 23,787 | 3,470 | 3,312 | 0 |
| 30 Jun 24 | 22,680 | 3,338 | 3,059 | 0 |
| 31 Mar 24 | 21,774 | 3,137 | 3,059 | 0 |
| 31 Dec 23 | 21,034 | 3,164 | 2,875 | 0 |
| 30 Sep 23 | 19,971 | 2,965 | 2,752 | 0 |
| 30 Jun 23 | 19,184 | 2,743 | 2,637 | 0 |
| 31 Mar 23 | 18,521 | 2,663 | 2,523 | 0 |
| 31 Dec 22 | 17,842 | 2,123 | 2,436 | 0 |
| 30 Sep 22 | 16,670 | 2,004 | 2,375 | 0 |
| 30 Jun 22 | 15,756 | 1,847 | 2,326 | 0 |
| 31 Mar 22 | 14,908 | 1,868 | 2,250 | 0 |
| 31 Dec 21 | 14,069 | 2,367 | 2,351 | 0 |
| 30 Sep 21 | 14,026 | 2,473 | 2,269 | 0 |
| 30 Jun 21 | 14,064 | 2,518 | 2,037 | 0 |
| 31 Mar 21 | 13,762 | 2,385 | 2,096 | 0 |
| 31 Dec 20 | 13,817 | 2,018 | 1,908 | 0 |
| 30 Sep 20 | 13,142 | 1,724 | 1,833 | 0 |
| 30 Jun 20 | 12,203 | 1,476 | 1,700 | 0 |
| 31 Mar 20 | 11,344 | 1,208 | 1,785 | 0 |
| 31 Dec 19 | 10,463 | 879 | 1,719 | 0 |
| 30 Sep 19 | 9,972 | 834 | 1,677 | 0 |
| 30 Jun 19 | 10,099 | 780 | 1,631 | 0 |
| 31 Mar 19 | 10,001 | 804 | 1,659 | 0 |
| 31 Dec 18 | 9,523 | 666 | 1,601 | 0 |
| 30 Sep 18 | 9,223 | 582 | 1,599 | 0 |
| 30 Jun 18 | 9,272 | 463 | 1,474 | 0 |
| 31 Mar 18 | 9,127 | 358 | 1,534 | 0 |
| 31 Dec 17 | 8,918 | 343 | 1,528 | 0 |
| 30 Sep 17 | 8,949 | 275 | 1,550 | 0 |
| 30 Jun 17 | 8,015 | 187 | 1,492 | 0 |
| 31 Mar 17 | 7,672 | 113 | 1,547 | 0 |
| 31 Dec 16 | 7,926 | 70 | 1,475 | 0 |
| 30 Sep 16 | 7,948 | 136 | 1,458 | 0 |
| 30 Jun 16 | 8,699 | 481 | 1,424 | 0 |
| 31 Mar 16 | 8,933 | 785 | 1,270 | 0 |
| 31 Dec 15 | 8,536 | 1,093 | 1,585 | 0 |
| 30 Sep 15 | 8,495 | 1,191 | 1,397 | 0 |
| 30 Jun 15 | 8,045 | 1,154 | 728 | 0 |
Quality Earnings: MARKSANS has high quality earnings.
Growing Profit Margin: MARKSANS's current net profit margins (14.2%) are lower than last year (14.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MARKSANS's earnings have grown by 13.5% per year over the past 5 years.
Accelerating Growth: MARKSANS's earnings growth over the past year (9.8%) is below its 5-year average (13.5% per year).
Earnings vs Industry: MARKSANS earnings growth over the past year (9.8%) did not outperform the Pharmaceuticals industry 11.7%.
Return on Equity
High ROE: MARKSANS's Return on Equity (13.8%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/29 10:53 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Marksans Pharma Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ranjit Kapadia | Centrum Broking Limited |
| Maitri Sheth | Choice Equity Broking Private Limited |
| Nitin Agarwal | DAM Capital Advisors |